Dr Christopher Rowe

Dr Christopher Rowe

Lecturer

School of Medicine and Public Health

Career Summary

Biography

I am an Adult Endocrinologist (Fellow of the Royal Australasian College of Physicians), with practice at John Hunter Hospital and at Newcastle Endocrinology, as well as Clinical Lecturer at the University of Newcastle. 

I have recently returned from a visiting Fellowship to the Institute of Metabolism and Systems Research at the University of Birmingham and Queen Elizabeth Hospital, with Professor Chris McCabe and Dr Kristien Boelaert.  

My primary area of research relates to thyroid nodules and thyroid cancer, although I am active across a wide range of projects in diabetes, pregnancy and endocrinology in the basic and clinical spheres.  

My current doctoral studies through the University of Newcastle School of Medicine and Public Health are investigating new diagnostic and therapetic targets for thyroid cancer.  In particular, our group is examining the utility of the TSH receptor as a specific theranostic marker for drug delivery, in collaboration with the John Hunter Hospital Thyroid Cancer Multidisciplinary Team, the Hunter Cancer Biobank and Pathology North (Hunter).  I am also collaborating with Professor Hubert Hondermarck in the School of Biomedical Sciences and Pharmacy to study the role of neurotrophins as biomarkers and therapeutic targets in thyroid malignancy.

I am active in a number of clinical research projects studying the impact of visceral fat on insulin resistance in Type 1 Diabetes, and management of diabetes in pregnancy.

I am an inaugural recipient of a Clinical Research Fellowship (Hunter New England Local Health District), and my recent research has been supported by the Hunter Cancer Research Alliance, Avant Mutual Group, the University of Newcastle, and the John Hunter Hospital Charitable Trust. 



Qualifications

  • Bachelor of Medicine, Bachelor of Surgery (Hons), University of New South Wales
  • Bachelor of Science (Medicine), University of New South Wales

Keywords

  • Diabetes Mellitus
  • endocrinology
  • insulin resistance
  • pregnancy
  • thyroid

Fields of Research

Code Description Percentage
110306 Endocrinology 60
110901 Autonomic Nervous System 20
110102 Medical Biochemistry: Carbohydrates 20

Professional Experience

UON Appointment

Title Organisation / Department
Lecturer University of Newcastle
School of Medicine and Public Health
Australia

Awards

Prize

Year Award
2019 ADIPS Outstanding Abstract Award (Travel Grant)
Australasian Diabetes in Pregnancy Society
2016 Australian Diabetes Society Travel Grant (Outstanding Abstract)
Australian Diabetes Society (ADS)
2016 Australasian Diabetes in Pregnancy Society Travel Grant (Outstanding Abstract)
Australian Diabetes in Pregnancy Society (ADIPS)
2015 Endocrine Society (USA) Travel Grant (Outstanding Abstract)
The Endocrine Society

Invitations

Speaker

Year Title / Rationale
2019 Maternal hyperglycaemia and neonatal hypoglycaemia following betamethasone can be safely reduced by a pregnancy-specific algorithm-driven intravenous insulin infusion in women with gestational diabetes

Administering betamethasone to women with gestational diabetes causes maternal hyperglycaemia, and is associated with neonatal hypoglycaemia 1.  There are limited data to guide interventions to control maternal hyperglycaemia in this population, including treatment targets and endpoints.

Here we discuss results of a recently published cohort study 2 reporting safety and efficacy of a novel Pregnancy-specific Intravenous Insulin-Glucose Infusion (P-IVI) protocol, validated at John Hunter Hospital since 2017, as compared to the previous standard of care (a generic Adult IntraVenous Insulin protocol (A-IVI) not designed for pregnancy).   Primary outcome was percentage of on-infusion time with capillary blood glucose (BGL) at target (3.8-7mmol/L).  Secondary outcomes were percentage time with critical hyperglycaemia (BGL>10mmol/L) or hypoglycaemia (BGL <3.8mmol/L), and incidence of neonatal hypoglycaemia (BGL<2.5mmol/L in first 48 hours if betamethasone given within 2 days of birth). 

We found that on-infusion time at target was 68% (95%CI 64-71%) for P-IVI compared to 55% (95%CI 50-60%) for AIVI (p=0.0002).  Time with critical hyperglycaemia was lower with P-IVI compared to A-IVI (0% vs 2%, p=0.02), with lower incidence of maternal hypoglycaemia (2% vs 12%, p=0.02).  Neonatal hypoglycaemia occurred in 29% of births following P-IVI, compared to 54% births following A-IVI (p=0.03).  A multiple logistic regression model adjusting for potential confounders gave an odds ratio for neonatal hypoglycaemia with P-IVI of 0.27 (95%CI 0.10-0.76, p=0.01).

We conclude that an infusion protocol designed for pregnancy effectively controlled maternal hyperglycaemia following betamethasone.  This is the first protocol to show a reduction in betamethasone-associated neonatal hypoglycaemia, linked with optimum maternal glycaemic control.

  1. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women at Risk for Late Preterm Delivery. N Engl J Med. 2016;374(14):1311-1320.
  2. Rowe CW, Putt E, Brentnall O, Gebuehr A, Allabyrne J, Woods A, Wynne K. An intravenous insulin protocol designed for pregnancy reduces neonatal hypoglycaemia following betamethasone administration in women with gestational diabetes. Diabet Med. 2018.
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (1 outputs)

Year Citation Altmetrics Link
2019 Rowe C, Boelaert K, Smith R, 'Thyroid Cancer During Pregnancy and Lactation', Maternal-Fetal and Neonatal Endocrinology: Physiology, Pathophysiology, and Clinical Management, Academic Press: Elsevier, United States of America 317-327 (2019)
DOI 10.1016/B978-0-12-814823-5.00020-9
Co-authors Roger Smith

Journal article (9 outputs)

Year Citation Altmetrics Link
2019 Rowe CW, Arthurs S, O Neill CJ, Hawthorne J, Carroll R, Wynne K, Bendinelli C, 'High-dose preoperative cholecalciferol to prevent post-thyroidectomy hypocalcaemia: A randomized, double-blinded placebo-controlled trial', Clinical Endocrinology, 90 343-350 (2019) [C1]

© 2018 John Wiley &amp; Sons Ltd. Objective: Post-thyroidectomy hypocalcaemia is a significant cause of morbidity and prolonged hospitalization, usually due to transient parathy... [more]

© 2018 John Wiley & Sons Ltd. Objective: Post-thyroidectomy hypocalcaemia is a significant cause of morbidity and prolonged hospitalization, usually due to transient parathyroid gland damage, treated with calcium and vitamin D supplementation. We present a randomized, double-blinded placebo-controlled trial of preoperative loading with high-dose cholecalciferol (300¿000 IU) to reduce post-thyroidectomy hypocalcaemia. Patients and Measurements: Patients (n¿=¿160) presenting for thyroidectomy at tertiary hospitals were randomized 1:1 to cholecalciferol (300¿000¿IU) or placebo 7¿days prior to thyroidectomy. Ten patients withdrew prior to surgery. The primary outcome was post-operative hypocalcaemia (corrected calcium <2.1¿mmol/L in first 180¿days). Results: The study included 150 patients undergoing thyroidectomy for Graves¿ disease (31%), malignancy (20%) and goitre (49%). Mean pre-enrolment vitamin D was 72¿±¿26¿nmol/L. Postoperative hypocalcaemia occurred in 21/72 (29%) assigned to cholecalciferol and 30/78 (38%) participants assigned to placebo (P¿=¿0.23). There were no differences in secondary end-points between groups. In pre-specified stratification, baseline vitamin D status did not predict hypocalcaemia, although most individuals were vitamin D replete at baseline. Post-hoc stratification by day 1 parathyroid hormone (PTH) (<10¿pg/mL, low vs =10¿pg/mL, normal) was explored due to highly divergent rates of hypocalcaemia in these groups. Using a Cox regression model, the hazard ratio for hypocalcaemia in the cholecalciferol group was 0.56 (95%CI 0.32-0.98, P¿=¿0.04) after stratification for Day 1 PTH. Further clinical benefits were observed in these subgroups. Conclusions: Pre-thyroidectomy treatment with high-dose cholecalciferol did not reduce the overall rate of hypocalcaemia following thyroidectomy. In subgroups stratified by day 1 PTH status, improved clinical outcomes were noted.

DOI 10.1111/cen.13897
Citations Web of Science - 1
Co-authors Katie-Jane Wynne
2019 Rowe CW, Putt E, Brentnall O, Gebuehr A, Allabyrne J, Woods A, Wynne K, 'An intravenous insulin protocol designed for pregnancy reduces neonatal hypoglycaemia following betamethasone administration in women with gestational diabetes', Diabetic Medicine, 36 228-236 (2019) [C1]

© 2018 Diabetes UK Aims: Marked hyperglycaemia is common following betamethasone administration in women with gestational diabetes (GDM), and may contribute to neonatal hypoglycae... [more]

© 2018 Diabetes UK Aims: Marked hyperglycaemia is common following betamethasone administration in women with gestational diabetes (GDM), and may contribute to neonatal hypoglycaemia. Validated protocols to deliver glycaemic stability following betamethasone are lacking. We hypothesized that an intravenous insulin (IVI) protocol for pregnancy-specific glycaemic targets (Pregnancy-IVI) would achieve greater at-target glycaemic control than a generic adult intravenous insulin protocol (Adult-IVI), and may reduce neonatal hypoglycaemia. Methods: A retrospective cohort study of the performance Adult-IVI and Pregnancy-IVI following betamethasone in GDM, sequentially implemented at a tertiary hospital, without change in indication for IVI. Cases were identified by electronic record search. Primary outcome was percentage of on-IVI time with at-target glycaemia [blood glucose level (BGL) 3.8¿7¿mmol/l]. Secondary outcomes were time with critical hyperglycaemia (BGL >¿10¿mmol/l), occurrence of maternal hypoglycaemia (BGL <¿3.8¿mmol/l), and incidence of neonatal hypoglycaemia (BGL =¿2.5¿mmol/l) if betamethasone was administered within 48¿h of birth. Results: The cohorts comprised 151 women (Adult-IVI n¿=¿86; Pregnancy-IVI n¿=¿65). The primary outcome was 68% time-at-target [95% confidence interval (CI) 64¿71%) for Pregnancy-IVI compared with 55% (95% CI 50¿60%) for Adult-IVI (P¿=¿0.0002). Critical maternal hyperglycaemia (0% vs. 2%, P¿=¿0.02) and hypoglycaemia (2% vs. 12%, P¿=¿0.02) were both lower with Pregnancy-IVI than Adult-IVI. Neonatal hypoglycaemia was less common after Pregnancy-IVI (29%) than after Adult-IVI (54%, P¿=¿0.03). A multiple logistic regression model adjusting for potential confounders gave an odds ratio for neonatal hypoglycaemia with Pregnancy-IVI of 0.27 (95% CI 0.10¿0.76, P¿=¿0.01). Conclusions: An IVI protocol designed for pregnancy effectively controlled maternal hyperglycaemia following betamethasone administration in GDM. This is the first intervention to show a reduction in betamethasone-associated neonatal hypoglycaemia, linked with optimum maternal glycaemic control.

DOI 10.1111/dme.13864
Citations Scopus - 1Web of Science - 1
Co-authors Katie-Jane Wynne
2019 Marlow AL, Rowe CW, Anderson D, Wynne K, King BR, Howley P, Smart CE, 'Young children, adolescent girls and women with type 1 diabetes are more overweight and obese than reference populations, and this is associated with increased cardiovascular risk factors.', Diabetic medicine : a journal of the British Diabetic Association, 36 1487-1493 (2019) [C1]
DOI 10.1111/dme.14133
Co-authors Katie-Jane Wynne, Bruce King, Peter Howley, Carmel Smart
2018 Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, et al., 'The neurotrophic tyrosine kinase receptor TrkA and its ligand NGF are increased in squamous cell carcinomas of the lung', SCIENTIFIC REPORTS, 8 (2018) [C1]
DOI 10.1038/s41598-018-26408-2
Citations Scopus - 3Web of Science - 3
Co-authors Marjorie Walker, Hubert Hondermarck, Sam Faulkner, Rick Thorne, Phillip Jobling
2018 Faulkner S, Jobling P, Rowe CW, Rodrigues Oliveira SM, Roselli S, Thorne RF, et al., 'Neurotrophin Receptors TrkA, p75

© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear.... [more]

© 2018 American Society for Investigative Pathology Neurotrophin receptors are emerging targets in oncology, but their clinicopathologic significance in thyroid cancer is unclear. In this study, the neurotrophin tyrosine receptor kinase TrkA (also called NTRK1), the common neurotrophin receptor p75NTR, and the proneurotrophin receptor sortilin were analyzed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and normal thyroid tissues (n = 62). TrkA was detected in 20% of thyroid cancers, compared with none of the benign samples (P = 0.0007). TrkA expression was independent of histologic subtypes but associated with lymph node metastasis (P = 0.0148), suggesting the involvement of TrkA in tumor invasiveness. Nerves in the tumor microenvironment were positive for TrkA. p75NTR was overexpressed in anaplastic thyroid cancers compared with papillary and follicular subtypes (P < 0.0001). Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P < 0.0001). Neurotrophin receptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels. Functional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against TrkA, p75NTR, and sortilin decreased cell survival and cell migration through decreased SRC and ERK activation. Together, these data reveal TrkA, p75NTR, and sortilin as potential therapeutic targets in thyroid cancer.

DOI 10.1016/j.ajpath.2017.09.008
Citations Scopus - 7Web of Science - 6
Co-authors Marjorie Walker, John Attia, Sam Faulkner, Chenchen Jiang, Xu Zhang, Hubert Hondermarck, Rick Thorne, Phillip Jobling, Christopher Oldmeadow
2017 Rowe CW, Paul JW, Gedye C, Tolosa JM, Bendinelli C, McGrath S, Smith R, 'Targeting the TSH receptor in thyroid cancer', Endocrine-Related Cancer, 24 R191-R202 (2017) [C1]

© 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The exis... [more]

© 2017 Society for Endocrinology Printed in Great Britain. Recent advances in the arena of theranostics have necessitated a re-examining of previously established fields. The existing paradigm of therapeutic thyroid-stimulating hormone receptor (TSHR) targeting in the post-surgical management of differentiated thyroid cancer using levothyroxine and recombinant human thyroid-stimulating hormone (TSH) is well understood. However, in an era of personalized medicine, and with an increasing awareness of the risk profile of longstanding pharmacological hyperthyroidism, it is imperative clinicians understand the molecular basis and magnitude of benefit for individual patients. Furthermore, TSHR has been recently re-conceived as a selective target for residual metastatic thyroid cancer, with pilot data demonstrating effective targeting of nanoparticles to thyroid cancers using this receptor as a target. This review examines the evidence for TSHR signaling as an oncogenic pathway and assesses the evidence for ongoing TSHR expression in thyroid cancer metastases. Priorities for further research are highlighted.

DOI 10.1530/ERC-17-0010
Citations Scopus - 7Web of Science - 5
Co-authors Roger Smith, Craig Gedye, Jonathan Paul
2017 Rowe CW, Haider AS, Viswanathan D, Jones M, Attia J, Wynne K, Acharya S, 'Insulin resistance correlates with maculopathy and severity of retinopathy in young adults with Type 1 Diabetes Mellitus', Diabetes Research and Clinical Practice, 131 154-160 (2017) [C1]

© 2017 Elsevier B.V. Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-se... [more]

© 2017 Elsevier B.V. Aims To assess the relationship between insulin resistance (IR), retinopathy and maculopathy in young adults with Type 1 diabetes mellitus. Methods A cross-sectional study at a regional Australian tertiary hospital. Retinal pathology, assessed by colour fundus photography, was correlated with two surrogate measures of IR: estimated Glucose Disposal Rate (eGDR) and Insulin Sensitivity Score (ISS), where lower scores reflect greater IR. Results 107 patients were recruited, with mean age 24.7¿years, 53% male, and mean duration of disease 10.8¿years. Mean eGDR scores (5.6¿vs 8.0 p¿<¿0.001) and ISS (4.7¿vs 7.9, p¿<¿0.001) were lower in subjects having at least moderate non-proliferative diabetic retinopathy (NPDR; relative to nil/mild-NPDR). Similarly, mean eGDR (4.2¿vs 6.2, p¿=¿0.001) and ISS (3.8¿vs 6.1, p¿=¿0.003) were lower in patients with maculopathy. Multivariate logistic regression modelling was used to control for confounding. For retinopathy severity, a unit increase in eGDR or ISS (representing lower IR) was associated with a 50% decrease in odds of moderate-NPDR or worse (eGDR OR 0.5, 95%CI 0.32¿0.77, p¿=¿0.002; ISS OR 0.49, 95%CI 0.29¿0.84, p¿=¿0.01). A unit increase in eGDR or ISS was associated with a 46¿56% decrease in odds of maculopathy (eGDR OR 0.54, 95%CI 0.37¿0.81, p¿=¿0.003; ISS OR 0.44, 95%CI 0.22¿0.88, p¿=¿0.02). Conclusions IR correlates with more severe retinopathy in young adults with Type 1¿DM. This is the first description of a correlation between IR and maculopathy in Type 1¿DM, warranting further evaluation. Prospective studies examining whether reducing IR can improve microvascular complications are required.

DOI 10.1016/j.diabres.2017.06.022
Citations Scopus - 1Web of Science - 1
Co-authors Katie-Jane Wynne, John Attia
2016 Rowe CW, Murray K, Woods A, Gupta S, Smith R, Wynne K, 'Management of metastatic thyroid cancer in pregnancy: risk and uncertainty', ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, (2016)
DOI 10.1530/EDM-16-0071
Citations Web of Science - 2
Co-authors Roger Smith, Katie-Jane Wynne
2016 Rowe CW, Bendinelli C, McGrath S, 'Charting a course through the CEAs: diagnosis and management of medullary thyroid cancer', Clinical Endocrinology, 85 340-343 (2016) [C3]
DOI 10.1111/cen.13114
Citations Scopus - 1Web of Science - 1
Show 6 more journal articles

Conference (24 outputs)

Year Citation Altmetrics Link
2019 Rowe C, Woods A, Wynne K, 'Transient extreme insulin resistance in pregnancy following betamethasone administration managed with high-dose intravenous insulin: case series and literature review.', Sydney, Australia (2019)
Co-authors Katie-Jane Wynne
2019 Rowe C, Delbridge M, Brown K, Watkins B, Addley J, Wynne K, 'An insulin infusion designed for pregnancy provides comparable glycaemic control following betamethasone in women with gestational and pre-existing diabetes, although hypoglycaemia is more common in pre-existing diabetes.', Sydney, Australia (2019)
Co-authors Katie-Jane Wynne
2019 Rowe C, Boelaert K, Colley S, Ballard M, Pracey P, Giblet N, Sharma N, 'Integrated thyroid nodule risk stratification using BTA U (ultrasound) and Thy (cytology): outcomes at a large tertiary centre.', Sydney, Australia (2019)
2019 Rowe C, 'Reducing neonatal hypoglycemia following antenatal corticosteroids in women with gestational diabetes', Sydney, Australia (2019)
2018 Rowe C, Dill T, Clarke M, Paul J, Gedye C, King S, Hondermarck H, 'A methodology for validating automated digital whole-slide analysis of immunohistochemical biomarkers using open source software (QuPath).', Newcastle, Australia (2018)
Co-authors Craig Gedye, Jonathan Paul, Hubert Hondermarck
2018 Kuehn J, Rowe CW, Amico F, Ward A, Bendinelli C, 'Management of an intrathyroidal cystic parathyroid gland with post-traumatic haemorrhagic transformation causing acute airway compromise', Adelaide, Australia (2018)
2018 Croker E, Chew C, Weigner J, Bendinelli C, McGrath S, Rowe CW, 'The whole is greater than the sum of its parts: synthesised triple-assessment of thyroid nodules optimises pre-operative risk-stratification.', Adeladie (2018)
2018 Rowe CW, Dill T, Faulkner S, Griffin N, Jobling P, King S, et al., 'Increased nerve density around papillary thyroid cancers and primary thyroid cancers with nodal metastases.', Adelaide (2018)
Co-authors Hubert Hondermarck, Roger Smith, Jonathan Paul, Craig Gedye, Phillip Jobling
2018 Pradeepan S, Pullen S, Viljevac N, Murdoch T, Bone E, Stormer J, et al., 'VLED is an effective real-life treatment for severe complex obesity, and improves obstructive sleep apnoea', Brisbane, Australia (2018)
Co-authors Katie-Jane Wynne, Surinder Baines
2018 Faulkner S, Rowe CW, Gaom F, Griffin N, Walker MM, Denham J, et al., 'Nerve Dependence in Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Sam Faulkner, Jim Denham, Marjorie Walker, Phillip Jobling, Hubert Hondermarck
2018 Gao F, Griffin N, Faulkner S, Rowe CW, Williams L, Roselli S, Thorne RF, 'The Neurotrophic Tyrosine Kinase Receptor TrkA and Its Ligand NGF are Increased in Squamous Cell Carcinomas of the Lung', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Rick Thorne, Sam Faulkner
2018 Griffin N, Hondermarck H, Gao F, Faulkner S, Jobling P, Rowe CW, 'Neurotrophic Growth Factors and Their Receptors as Novel Therapeutic Targets in Esophageal Cancer', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2018)
Co-authors Hubert Hondermarck, Phillip Jobling, Sam Faulkner
2018 Rowe C, Dill T, King S, Gedye C, Paul J, Tolosa JM, Smith R, 'Thyroid cancers resected in patients with concurrent TSH-receptor stimulation have higher levels of sodium-iodide symporter (NIS) expression', CLINICAL ENDOCRINOLOGY, Perth, AUSTRALIA (2018)
Co-authors Craig Gedye, Jonathan Paul, Roger Smith
2017 Marlow A, Rowe C, Anderson D, Wynne K, King BR, Smart CE, 'Children and young adults with type 1 diabetes are more overweight and obese than reference populations, and this worsens with age', Tasmania (2017)
Co-authors Katie-Jane Wynne, Carmel Smart, Bruce King
2017 Croker E, Tan HLE, Rowe C, 'Diabetic ketoacidosis (DKA) in patients on maintenance dialysis: case series and literature review', Perth, Western Australia (2017)
2017 Rowe C, Tolosa Gonzalez JT, Faulkner S, Paul JW, Gedye C, McGrath S, et al., 'The precursor for nerve growth factor (proNGF) is detectable in the rinse of fine needle aspiration biopsy of thyroid cancer', Boston, Massachussetts (2017)
Co-authors Jonathan Paul, Hubert Hondermarck, Craig Gedye, Roger Smith
2016 Faulkner S, Jobling P, Rowe C, Oldmeadow C, Roselli S, Thorne R, et al., 'CLINICOPATHOLOGICAL SIGNIFICANCE OF PRONGF RECEPTORS IN THYROID CANCER', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2016)
Co-authors Hubert Hondermarck, Marjorie Walker, Phillip Jobling, John Attia, Rick Thorne, Christopher Oldmeadow
2016 Rowe C, Wynne K, Acharya SA, 'High rates of obesity in young adults with type 1 diabetes.', Gold Coast (2016)
Co-authors Katie-Jane Wynne
2016 Rowe C, Pain O, Ronthal R, Buckmaster C, Morrison S, Wynne K, 'Betamethasone leads to acute hyperglycaemia in women with GDM.', Gold Coast (2016)
Co-authors Katie-Jane Wynne
2015 Rowe C, McGrath S, Smith R, 'Response of TSH-Secreting Pituitary Tumours to Somatostatin Analogues in Five Patients', San Diego, California (2015)
DOI 10.1210/endo-meetings.2015.BCHVD.11.SAT-256
Co-authors Roger Smith
2015 Rowe C, mcgrath S, 'Parathyroid Ultrasound As Screening Tool for Familial Hypocalciuric Hypercalcemia', San Diego, California (2015)
DOI 10.1210/endo-meetings.2015.BCHVD.11.SAT-256
2015 Rowe C, Wynne K, Luu J, Quach T, Jackel D, Perry L, Acharya S, 'Emergency Department (ED) utilisation in young adults with type 1 diabetes (T1D) under care of a tertiary clinic.', Adelaide (2015)
Co-authors Katie-Jane Wynne, Lin Perry
2014 Rowe C, McGrath SA, 'Pre-operative localisation of parathyroid adenoma with ultrasound and sestamibi scintigraphy in primary hyperparathyroidism review of single centre experience.', Melbourne, Australia (2014)
2013 Rowe C, Joshi T, Wynne K, 'Remembering Halsted Mediastinal Mass Complicating Graves disease', Madrid, Spain (2013)
Co-authors Katie-Jane Wynne
Show 21 more conferences
Edit

Grants and Funding

Summary

Number of grants 5
Total funding $472,528

Click on a grant title below to expand the full details for that specific grant.


20181 grants / $397,528

Hunter Cancer Biobank$397,528

Funding body: NSW Health Pathology - Pathology North

Funding body NSW Health Pathology - Pathology North
Project Team Professor Marjorie Walker, Laureate Professor Rodney Scott, Conjoint Professor Stephen Ackland, Mrs Susan Goode, Associate Professor Pradeep Tanwar, Associate Professor Nikki Verrills, Professor Hubert Hondermarck, Doctor Simon King, Mr Ricardo Vilain, Associate Professor Nikola Bowden, Doctor Kelly Kiejda, Associate Professor Simon Keely, Doctor Christopher Rowe
Scheme Research Grant
Role Investigator
Funding Start 2018
Funding Finish 2019
GNo G1800704
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

20171 grants / $15,000

Hunter Cancer Research Alliance (HCRA)$15,000

Funding body: Hunter Cancer Research Alliance (HCRA)

Funding body Hunter Cancer Research Alliance (HCRA)
Project Team

Christopher Rowe, Hubert Hondermarck, Roger Smith, Shaun McGrath, Simon King, Marjorie Walker, John Attia

Scheme HCRA Implementation Flagship program
Role Lead
Funding Start 2017
Funding Finish 2017
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

20162 grants / $40,000

AVANT Doctors in Training Scholarship$25,000

Funding body: AVANT Mutual Group

Funding body AVANT Mutual Group
Project Team

Christopher Rowe, Jonathan Paul, Jorge Tolosa, Roger Smith

Scheme Doctors in Training Scholarship Scheme
Role Lead
Funding Start 2016
Funding Finish 2016
GNo
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON N

Hunter New England Clinical Research Fellowship$15,000

Funding body: Hunter New England Health

Funding body Hunter New England Health
Project Team

Christopher Rowe

Scheme Clinical Research Fellowship
Role Lead
Funding Start 2016
Funding Finish 2018
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N

20151 grants / $20,000

NewDIAB: Understanding Type 1 Diabetes in Newcastle$20,000

Funding body: John Hunter Charitable Trust

Funding body John Hunter Charitable Trust
Project Team

Christopher Rowe, Shamasunder Acharya, Lin Perry, Katie Wynne

Scheme John Hunter Charitable Trust Grant
Role Lead
Funding Start 2015
Funding Finish 2015
GNo
Type Of Funding Other Public Sector - State
Category 2OPS
UON N
Edit

Dr Christopher Rowe

Position

Lecturer
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email christopher.w.rowe@newcastle.edu.au
Link Twitter
Edit